Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

Registered drugNo placebo

Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Erdafitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Bladder cancer

Not recruiting

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Registered drugNo placebo

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Mitomycin
Sponsor:Janssen Cilag International

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

InvestigationalNo placebo

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Janssen Cilag International

Contact Research Centre

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trials Nivolumab36 clinical trials Mycophenolate Mofetil24 clinical trials Dapagliflozin23 clinical trials Cabozantinib22 clinical trials Cisplatin22 clinical trials Ipilimumab21 clinical trials Gemcitabine20 clinical trials Sodium Chloride17 clinical trials

Renal and urinary disorders – page 39

Conditions in this area

Clinical trials in Renal and urinary disorders

580 clinical trials

Genitourinary syndrome of menopause

Study on the Effectiveness of Platelet-Rich Plasma and Hyaluronic Acid vs. Estriol for Women with Menopausal Genitourinary Syndrome

Congenital cystic kidney disease

Study on the Safety and Effects of Tolvaptan for Infants and Young Children with Autosomal Recessive Polycystic Kidney Disease

Chronic kidney disease

Study on Reducing Protein in Urine for Patients with Chronic Kidney Disease Using Finerenone and Semaglutide

Bladder transitional cell carcinoma

Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy

Thyroid cancer+18

Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

Diabetic nephropathy

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Paroxysmal nocturnal haemoglobinuria

Study on the Long-Term Safety and Effects of OMS906 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sepsis+1

Study on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury

Bladder cancer stage 0 with cancer in situ

Study of ONCOFID-P-B for Patients with Bladder Carcinoma in Situ Unresponsive to BCG Treatment

Bladder transitional cell carcinoma

Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy

Bladder cancer

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Bladder transitional cell carcinoma

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.